Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€0.31

€0.31

-1.270%
-0.004
-1.270%
-

-

 
10.04.26 / Tradegate WKN: A3D1K3 / Name: Bionxt Solutions / Stock / Small Cap /

Bionxt Solutions Inc. Stock

A loss of -1.270% shows a downward development for Bionxt Solutions Inc..
So far the community has only identified positive things for Bionxt Solutions Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Bionxt Solutions Inc. in the next few years

Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries

VANCOUVER, BC / ACCESS Newswire / April 7, 2026 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug

BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy

VANCOUVER, BC / ACCESS Newswire / March 30, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug

BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform

VANCOUVER, BC / ACCESS Newswire / March 24, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug